An overview on dosage forms and formulation strategies for vaccines and antibodies oral delivery

Madani, Faten; Hsein, Hassana; Busignies, Virginie; Tchoreloff, Pierre

doi:10.1080/10837450.2019.1689402

Cited by 22 publications

(11 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, another IgY-based immune interventions, the development of IgY antibodies with peptide-based immunization of hens, may provide oral-based therapeutics and prophylactics against this high priority coronavirus (Figure 3). For example, it could be a remarkable success if an effective reduction of SARS-CoV-2 viral load is achieved in the upper respiratory tract [105,112]. The use of chickens instead of other farm animals in the production of these antibodies allows industrial scale-up and its use in many countries worldwide where chicken farming is available.…”

Section: Discussionmentioning

confidence: 99%

Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?

et al. 2020

View full text Add to dashboard Cite

In the current worldwide pandemic situation caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the newest coronavirus disease (COVID-19), therapeutics and prophylactics are urgently needed for a large population. Some of the prophylaxis strategies are based on the development of antibodies targeting viral proteins. IgY antibodies are a type of immunoglobulin present in birds, amphibians, and reptiles. They are usually obtained from egg yolk of hyper-immunized hens and represent a relatively inexpensive source of antibodies. Specific IgY can be produced by immunizing chickens with the target antigen and then purifying from the egg yolk. Chicken IgY has been widely explored as a clinical anti-infective material for prophylaxis, preventive medicine, and therapy of infectious diseases. Administered non-systemically, IgY antibodies are safe and effective drugs. Moreover, passive immunization with avian antibodies could become an effective alternative therapy, as these can be obtained relatively simply, cost-efficiently, and produced on a large scale. Here, we highlight the potential use of polyclonal avian IgY antibodies as an oral prophylactic treatment for respiratory viral diseases, such as COVID-19, for which no vaccine is yet available.

show abstract

Section: Discussionmentioning

confidence: 99%

Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…One of the greatest advances in the field of biotechnology has been the discovery of mAbs, which have revolutionized the field of research and medicine. At the time of writing this paper, all approved and marketed mAbs are administered systemically via the parenteral route (10). The most common ways of parenteral application are intravenous (i.v.)…”

Section: Characteristics Of Biopharmaceuticalsmentioning

confidence: 99%

Formulation of biologics for alternative routes of administration: Current problems and perspectives

Stanković¹,

Tasić‐Kostov²

2022

Acta fac medic Naissensis

View full text Add to dashboard Cite

Introduction: Biologics (biopharmaceuticals) present new promising therapies for many diseases such as cancers, chronical inflammatory diseases and today's biggest challenge - COVID-19. Research: Today, most biologics have been synthetized using modern methods of biotechnology, in particular DNA recombinant technology. Current pharmaceutical forms of protein/peptide biopharmaceuticals are intended for parenteral route of administration due to their instability and large size of molecules. In order to improve patient compliance, many companies are working on developing adequate forms of biopharmaceuticals for alternative, non-invasive routes of administration. The aim of this work is to review current aspirations and problems in formulation of biopharmaceuticals for alternative (non-parenteral) routes of administration and to review the attempts to overcome them. These alternative routes of administration could be promising in prevention and treatment of COVID-19, among other serious diseases. Conclusion: The emphasis is on stabilizing monoclonal antibodies into special formulations and delivery systems; their application should be safer, more comfortable and reliable. When it comes to hormones, vaccines and smaller peptides, some companies have already registered drugs intended for nasal and oral delivery.

show abstract

“…Associated to vaccine formulation, stability during storage and transportation and the suitability of a vaccine product for mass administration need special attention [ 28 ]. Novel adjuvants and formulation strategies are being explored to allow the simplest manipulation of the vaccine doses [ 25 , 29 ], especially at large scale administration programs in which thermal stability is particularly demanded [ 30 ].…”

Section: Introductionmentioning

confidence: 99%

Recombinant vaccines in 2022: a perspective from the cell factory

et al. 2022

View full text Add to dashboard Cite

The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 pandemics have globally stressed the need for efficient, cost-effective vaccines against infectious diseases. Ideally, they should be based on transversal technologies of wide applicability. In this context, and pushed by the above-mentioned epidemiological needs, new and highly sophisticated DNA-or RNA-based vaccination strategies have been recently developed and applied at large-scale. Being very promising and effective, they still need to be assessed regarding the level of conferred long-term protection. Despite these fast-developing approaches, subunit vaccines, based on recombinant proteins obtained by conventional genetic engineering, still show a wide spectrum of interesting potentialities and an important margin for further development. In the 80’s, the first vaccination attempts with recombinant vaccines consisted in single structural proteins from viral pathogens, administered as soluble plain versions. In contrast, more complex formulations of recombinant antigens with particular geometries are progressively generated and explored in an attempt to mimic the multifaceted set of stimuli offered to the immune system by replicating pathogens. The diversity of recombinant antimicrobial vaccines and vaccine prototypes is revised here considering the cell factory types, through relevant examples of prototypes under development as well as already approved products.

show abstract

An overview on dosage forms and formulation strategies for vaccines and antibodies oral delivery

Cited by 22 publications

References 159 publications

Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?

Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?

Formulation of biologics for alternative routes of administration: Current problems and perspectives

Recombinant vaccines in 2022: a perspective from the cell factory

Contact Info

Product

Resources

About